Growth Metrics

Solid Biosciences (SLDB) Operating Income: 2016-2024

Historic Operating Income for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$129.7 million.

  • Solid Biosciences' Operating Income fell 79.19% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of -$129.7 million for FY2024, which is 24.44% down from last year.
  • Solid Biosciences' Operating Income amounted to -$129.7 million in FY2024, which was down 24.44% from -$104.3 million recorded in FY2023.
  • In the past 5 years, Solid Biosciences' Operating Income registered a high of -$72.3 million during FY2021, and its lowest value of -$129.7 million during FY2024.
  • Over the past 3 years, Solid Biosciences' median Operating Income value was -$106.5 million (recorded in 2022), while the average stood at -$113.5 million.
  • Per our database at Business Quant, Solid Biosciences' Operating Income grew by 25.91% in 2020 and then slumped by 47.33% in 2022.
  • Yearly analysis of 5 years shows Solid Biosciences' Operating Income stood at -$88.4 million in 2020, then increased by 18.27% to -$72.3 million in 2021, then slumped by 47.33% to -$106.5 million in 2022, then increased by 2.07% to -$104.3 million in 2023, then dropped by 24.44% to -$129.7 million in 2024.